Form 4: Surrozen CEO Craig Parker Acquires 100,000 Stock Options

Surrozen's CEO, Craig Parker, has been granted 100,000 stock options, exercisable starting February 1, 2025, according to a recent SEC filing.

Summary

• Craig Parker, the CEO of Surrozen, Inc., has acquired 100,000 stock options.
• These options were granted on January 17, 2025, with an exercise price of $12.08 per share.
• The options vest in 48 equal monthly installments, beginning on February 1, 2025, contingent on Parker's continued service.
• The options expire on January 17, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CEO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 48 months is typical for such grants, ensuring long-term commitment from the executive.
• The exercise price of $12.08 is specific to Surrozen's stock and would need to be compared to similar grants at comparable companies to assess its relative value.

Stakeholder Impact

• Shareholders may view this positively as it incentivizes the CEO to increase company value.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, executive compensation, SEC Form 4, Surrozen, Craig Parker, insider trading